Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells.
about
Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variantsEvaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response.A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancerCellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models.Review of the management of relapsed small-cell lung cancer with amrubicin hydrochloride.Antitumor agents 294. Novel E-ring-modified camptothecin-4β-anilino-4'-O-demethyl-epipodophyllotoxin conjugates as DNA topoisomerase I inhibitors and cytotoxic agents.Topotecan, an active new antineoplastic agent: review and current status.Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancerRestoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment.Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells.High dose chemotherapy without hematopoietic cell support for the treatment of refractory lymphoma.Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors.The cell cycle effects of camptothecin.Current perspectives on camptothecins in cancer treatmentCombined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?Homocamptothecin-daunorubicin association overcomes multidrug-resistance in breast cancer MCF7 cells.In vitro antitumor activity of TAS-103, a novel quinoline derivative that targets topoisomerases I and II.
P2860
Q28361246-E98C24DC-DCA3-4F99-9B00-C23F0B4D6643Q31911584-530980B8-4746-48C6-A619-656AE33650F0Q33344326-5C273FDD-79D0-4BFB-9A66-195AFF10EBF0Q33366785-FE87CF7B-CA31-41D8-96C1-CC753DDF2C2BQ34768288-2D7F2DBD-B64B-4E64-9E3C-1C3A427F2BC8Q34789076-68A6C98F-510C-453B-B985-F47EFF6310C3Q36074267-D24AF0FB-42FD-4FE8-BE53-3A162A3E8334Q36179765-5CB4A797-9018-4298-BD14-B046F8734EF4Q36431537-45C67648-75BB-4A7C-A405-CBDDE0C4DB85Q36431552-8DBDCB51-4CCB-44A6-87D9-084C91781903Q38848784-065E0490-BA19-4C50-814E-0C85BD51309AQ40594608-2F269213-7169-486E-9508-4BECA8675CBFQ40622450-5EC6125C-F09C-4BD9-BC99-53A6A4D9450DQ40630446-20EC1DF2-9895-4E39-A080-26E1F5124272Q41307867-5FF22EE4-6644-4AD1-9536-8BD886A7CC1CQ42715927-79CDC437-B170-4ED4-9104-05DEC0AADD2FQ43007521-8731429F-F961-4CA1-99E2-ACF66CBD044AQ44043973-FCDC5DE0-9030-4DEC-AE0C-0A207195B5B3Q54959930-759EE8F8-7243-4D77-AC43-710DAFD4829B
P2860
Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Sequential administration of c ...... n colon carcinoma HT-29 cells.
@en
type
label
Sequential administration of c ...... n colon carcinoma HT-29 cells.
@en
prefLabel
Sequential administration of c ...... n colon carcinoma HT-29 cells.
@en
P2093
P1476
Sequential administration of c ...... n colon carcinoma HT-29 cells.
@en
P2093
Bertrand R
Kerrigan D
O'Connor PM
P304
P356
10.1016/0959-8049(92)90107-D
P577
1992-01-01T00:00:00Z